Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

This study has been terminated.
(slow enrollment)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Ruth He, Georgetown University
ClinicalTrials.gov Identifier:
NCT00881621
First received: April 13, 2009
Last updated: March 23, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)